Vaxcyte (PCVX)
Developer of high-valency bacterial vaccine candidates using cell-free protein synthesis.
Something off on this page? Send us feedback.
Develops high-valency bacterial vaccines using cell-free protein synthesis and site-specific conjugation, with pneumococcal candidates VAX-31, VAX-24, and VAX-XL at the center and earlier programs for Group A Strep and Shigella. With no approved products, funding supports trials and manufacturing scale-up rather than commercial sales.
Develops bacterial vaccines around a pneumococcal conjugate franchise led by VAX-31, now in late-stage adult trials and an infant study. VAX-24 has completed adult and infant mid-stage studies, while VAX-XL is a preclinical candidate for broader serotype coverage.
Pairs a licensed cell-free protein-synthesis system with carrier-sparing, site-specific conjugation to build high-valency vaccines. Beyond pneumococcus, VAX-A1 is in an early-stage adult study for Group A Strep, while VAX-GI for Shigella remains paused before further development.
Operates as a clinical-stage biotech with no approved products or product-sales revenue. Progress depends on clinical and regulatory outcomes, scaling a complex manufacturing process, continued financing, and contract partners for production and fill-finish.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Feb 25, 2026 | BTIG | Target | Target: $160 | Target: $89 |
| Nov 19, 2025 | Leerink Partners | Target | Target: $135 | Target: $77 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.49B · Total debt $115.4M · Total assets $3.14B · Shareholders' equity $2.76B
- Revenue
- $0
- Operating income
- −$302.8M
- Net income
- −$284.3M
No dividends on record.
| Institutions | 113.24% | 168.51M shares | |
|---|---|---|---|
| 351 holders · as of Jun 30, 2026 | |||
| Insiders | 0.86% | 1.28M shares | |
| 15 holders · as of Sep 9, 2026 | |||
| Strategic holders | 11.14% | 16.58M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 125.24% | ||
148.81M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 125.24%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.01% | 20.85M | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 12.07% | 17.97M | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 11.14% | 16.58M | filed May 15, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 8.20% | 12.21M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.11% | 12.07M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 9, 2026 | Jim Wassil | officer: EVP, Chief Scientific Ofc, COO | −1,334 | $59.52 |
| Sep 4, 2026 | Jim Wassil | officer: EVP, Chief Scientific Ofc, COO | −1,381 | $61.16 |
| Sep 1, 2026 | Jim Wassil | officer: CHIEF OPERATING OFFICER | −3,477 | $61.07 |
| Aug 3, 2026 | Andrew Guggenhime | officer: PRESIDENT AND CFO | −10,000 | $53.89 |
| Aug 3, 2026 | Jim Wassil | officer: CHIEF OPERATING OFFICER | −2,250 | $53.86 |
